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Abstract: The formation and maintenance of renal cell carcinomas (RCC) involve many cell types,
such as cancer stem and differentiated cells, endothelial cells, fibroblasts and immune cells. These all
contribute to the creation of a favorable tumor microenvironment to promote tumor growth and
metastasis. Extracellular vesicles (EVs) are considered to be efficient messengers that facilitate the
exchange of information within the different tumor cell types. Indeed, tumor EVs display features of
their originating cells and force recipient cells towards a pro-tumorigenic phenotype. This review
summarizes the recent knowledge related to the biological role of EVs, shed by renal tumor cells
and renal cancer stem cells in different aspects of RCC progression, such as angiogenesis, immune
escape and tumor growth. Moreover, a specific role for renal cancer stem cell derived EVs is described
in the formation of the pre-metastatic niche. We also highlight the tumor EV cargo, especially the
oncogenic miRNAs, which are involved in these processes. Finally, the circulating miRNAs appear to
be a promising source of biomarkers in RCC.
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1. Introduction
1.1. Renal Cell Carcinoma
Renal cell carcinoma (RCC) accounts for about 3% of all adult malignancies, being the twelfth most
common cancer in the world [1] and the third most common urogenital malignancy [2,3]. RCC has
the highest incidence in males and is one of the fastest increasing cancers, with this trend expected to
continue over the next 20 years [4].
Although different histological subtypes of RCC are described, clear-cell RCC occurs most
frequently and accounts for up to 80% of the RCC new cases. Clear-cell RCC is histologically
characterized by the presence of cancer cells with a transparent cytoplasm, which is due to the
accumulation of cholesterol esters, phospholipids and glycogen, and a well-defined cell membrane [5].
The other subtypes are papillary, chromophobe RCC and collecting-duct carcinoma. Papillary RCC
(15% of RCC) is the principal cancer type in kidney transplant recipients while chromophobe RCC,
which has the best prognosis, is quite rare [6].
Numerous genetic mutations are known to be involved in the pathogenesis and progression of
RCC and their identification would contribute to better diagnoses and prognoses [7]. This is crucial
in the development of new specific anti-cancer therapeutic strategies. The most common genetic
abnormality and the first described is the inactivation of the tumor suppressor von Hippel-Lindau
(VHL) by mutations, loss of heterozygosity or promoter hypermethylation [8]. The VHL protein
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is part of an E3 ubiquitin ligase multi-protein complex that regulates protein degradation through
proteasomes [9]. A loss of function in VHL generates an upregulation of hypoxic inducible factors
(HIF)-1α and 2α, which heterodimerize and stimulate the transcription of pro-angiogenic proteins,
namely vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) [10,11].
In particular, the activation of VEGF related pathways stimulates the proliferation, migration and
survival of endothelial cells. This genetic mutation occurs mainly in the clear-cell RCC subtype.
However, the inactivation of VHL per se is not sufficient to trigger RCC [1,10]. Other mutations have
been described to contribute to RCC initiation and progression, such as SWI/SNF chromatin-remodeling
complex gene PBRM1, BRCA1 associated protein-1, SET domain containing 2 and lysine K-specific
demethylase 6A [12]. Moreover, it has been shown that the mammalian target of rapamycin (mTOR)
pathway is significantly increased in RCC, which has a role in cell growth regulation in response to
hypoxia [13].
Several studies have recently analyzed the microRNA (miRNA) expression profiles of RCC tissue
specimens and have described an upregulation of miRNAs that target tumor-suppressors along with
a downregulation of miRNAs that target oncogenes [14,15]. Deregulated miRNAs influence key
molecules that are implicated in RCC progression, such as PTEN, VHL, HIF, VEGF and mTOR [16].
RCC is characterized by poor prognosis due to its high metastasis rate and difficulty in diagnosis.
In fact, over 60% of RCC are detected incidentally. Despite the improvement of imaging techniques,
about 20–30% of all patients at the time of diagnosis are already found to have metastatic cancer [1] and
about 30% of patients treated for localized RCC have a relapse in distant sites [17,18]. The prognosis of
patients with metastatic RCC is extremely poor with a 5-year survival rate of less than 10% [19,20].
The incomplete eradication of tumor cells is one of the factors of treatment failure and this may be due
to cellular heterogeneity. In particular, the presence of a small population of cancer stem cell (CSCs) is
attracting interest in the field as the major cause of tumor recurrence and resistance to therapy [21,22].
1.2. Renal Cancer Stem Cells
It is well established that the heterogeneity of solid tumors requires the presence of a subpopulation
of cancer cells with a stem-like phenotype, which are the so-called cancer stem cells. Their main feature
is their ability to differentiate into different cell types and sustain tumor growth [23]. This population
resides in a well-defined tumor area that participates in the maintenance of stem phenotype, which is
called niche, where CSCs and non-malignant cells may interact and influence each other [24]. Renal CSCs
have been distinguished in RCC by stem cell marker isolation or by functional characteristics, such as
sphere formation or dye exclusion [25]. In the first report in 2008, renal CSCs were identified as
a population expressing Endoglin (CD105) and other markers of stemness, such as Nestin, Nanog
and Oct-4 [22]. Renal CSCs have been shown to possess tumor initiating features and to differentiate
towards epithelial or endothelial phenotypes both in vitro and in vivo. CD105, a TGF-β co-receptor,
is expressed by many cell types, including mesenchymal and endothelial cells, and its expression is
correlated with poor prognosis in RCC [26]. Recently, a high expression of CXCR4 was proposed to be
a new CSC marker that correlates with more aggressive and metastatic RCC [27]. As an alternative,
Addla et al. defined renal CSC as the side population (SP), which has the characteristic of Hoechst
33342 dye exclusion [28]. The renal SP consists of cells with a high proliferation rate and stemness
properties [28]. Moreover, the sphere formation capacity was used to select renal CSCs in human
SK-RC-42 RCC cell line [29].
The origin of renal CSCs is controversial as they may derive from the transdifferentiation of normal
renal stem cells with mesenchymal phenotype or conversely from dedifferentiation of renal carcinoma
cells. Moreover, renal CSCs may participate in different steps of metastatic tumor progression
by sustaining tumor vascularization and the formation of a pre-metastatic niche, which possibly
occurs through a long range signaling network [30]. Among the mechanisms of communication
between primary tumor cells and other cellular components of the pre-metastatic lesion, many studies
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focused their attention on the emerging role of tumor-derived extracellular vesicles (EVs) and their
miRNA cargo.
2. Effects of RCC-Derived EVs
2.1. Tumor EVs
The term “extracellular vesicles”, recommended by the International Society of Extracellular
Vesicles (ISEV), defines a mixed population of vesicles with different dimensions that are released by
most cell types. These vesicles are classically divided into exosomes and microvesicles depending
on their biogenesis [31]. Based on recent studies, it is well recognized that EVs orchestrate both
physiological and pathological cell-to-cell communication through the delivery of cellular components
from the cell of origin to target cells. EVs have been isolated from the majority of biological fluids and
due to their stability in circulation, they could be a suitable diagnostic tool [32].
Several non-tumor cells, such as fibroblasts, endothelial cells and immune cells, participate in the
establishment of a favorable microenvironment to promote tumor progression and metastatization [33].
This phenomenon has been partially attributed to EV secretion [34]. In cancer patients, the number of
circulating tumor-derived EVs has been correlated with poor prognosis [35]. Indeed, EVs released
by tumor cells mediate different steps of tumor progression by the transfer of oncogenic molecules,
such as lipids, proteins and nucleic acids [36]. Apart from the fact that all tumor EVs trigger tumor
progression, it can be speculated that EVs released by CSCs may possess peculiar properties due to
their specific cargo. Among all the factors that are carried by RCC-EVs, a major role was ascribed to
miRNA content [32]. EV miRNA cargo has been shown to be involved in the regulation of multiple
targets in recipient cells, triggering all the pivotal processes during tumor progression.
In this review, we will dissect the different aspects of RCC-derived EVs in tumor progression and
metastatization. In particular, we will analyze the local effects of RCC-EVs within the tumor bulk, acting
on tumor cells and other non-tumor cells, such as mesenchymal and endothelial cells. In addition,
the systemic effects of RCC circulating EVs on immune cells and their action in the formation of
premetastatic niche will be discussed. Finally, we will report the EV cargo that is responsible for the
observed effects, including proteins, miRNAs and mRNAs (Figure 1).
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Figure 1. RCC-EV cargo. Molecules carried by RCC-EVs are described to play a role in tumor
progression through the promotion of angiogenesis, metastasis formation and immune escape.
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2.2. Pro-Angiogenic Ability of RCC-EVs
Tumor EVs have been extensively described to promote angiogenesis by carrying pro-angiogenic
mRNAs and miRNAs and modulating angiogenic pathways [37,38]. Several miRNAs, such as
miR-23a, miR-210, miR-135b, miR-494, miR-1246 and miR-9, carried by tumor EVs have been
demonstrated to be transferred to endothelial cells that display pro-angiogenic activity [39]. In particular,
in lung carcinoma, Hsu et al. have described that hypoxic cancer cells release EVs that are enriched
with miR-23a, which subsequently generate the accumulation of HIF-1α in endothelial cells and
promotes angiogenesis [40]. miR-23a directly suppresses prolyl hydroxylase 1 and 2 (PHD1 and 2),
which hydroxylates HIF-1α and facilitates its degradation through proteasomes [40]. Subsequently,
the presence of a high level of miR-23a favors the accumulation of HIF-1α in endothelial cells, resulting
in cell proliferation and migration [40]. Moreover, it has been described that under hypoxia, tumor cells
increase the release of exosomal miR-210 [41,42]. miR-210 targets receptor tyrosine kinase ligand
ephrin A3 and phospho-tyrosine phosphatase 1B, both negative regulators of VEGF, which causes
angiogenesis stimulation [39,42].
In RCC, hypoxic conditions stimulate the release of tumor cells-derived EVs that are enriched with
carbonic anhydrase 9 (CAIX), an HIF induced gene that regulates the proliferation and migration of
endothelial cells [43]. CAIX is a transmembrane protein overexpressed in several solid tumors, which is
involved in the regulation of intracellular pH and improves cancer cell survival [43,44]. In addition,
RCC-EVs are enriched with the azurocidin protein (AZU1) that modulates vascular permeability and
affects metastatization [45]. Specific pro-angiogenic and pro-tumorigenic roles have been attributed to
EVs released by renal CSCs [30,32]. In fact, EVs released by CSCs and undifferentiated tumor cells
carry several pro-angiogenic mRNAs, such as VEGF, FGF, angiopoietin 1, ephrin A3, MMP2 and
MMP9. These are all involved in the stimulation of endothelial cell growth, invasion and resistance to
apoptosis, which favors tumor progression and angiogenesis [30] (Figure 1).
2.3. Effect of RCC-EVs on Tumor Stroma
Another important factor that is necessary to stimulate tumor progression is the interaction of
tumor with stromal cells, especially mesenchymal stromal cells (MSCs) [46]. The effect of resident MSCs
on tumor progression is not well established and both pro-tumorigenic and anti-tumorigenic activity
have been reported [47]. This could be due to the effect of tumor secretoma that influences MSCs
towards different and even opposite characteristics. Lindoso et al. described that MSCs treated with
renal CSC-derived EVs were able to sustain tumor progression by enhancing MMP1, MMP2, MMP3,
collagen 4A3, CXCR4 and CXCR7 expression levels, which results in increased tumor vascularization
and proliferation [46]. MMPs are well known to regulate angiogenesis and tumor invasion and
metastasis [48] while CXCR4 is involved in MSC migration [49] and CXCR7 in MSC survival [50].
In addition, mesenchymal cells derived from bone marrow (BMDCs) are also involved in the
generation of an advantageous tumor microenvironment that leads to metastasis development. Recently,
it has been demonstrated that the exosomes released by melanoma cells influence BMDCs toward
a pro-vasculogenic and pro-metastatic phenotype. Tyrosinase-related protein-2, very late antigen 4,
heat shock protein 70 and MET oncoprotein were all found within exosomes, with the MET oncogene
being the principal molecule responsible for triggering the transformation of BMDCs [51].
2.4. Immunosuppressive Effects of RCC-EVs
Recent studies have proposed that tumour cells influence the immune response and inhibit T cell
proliferation, natural killer (NK) activation and dendritic cell (DC) differentiation through the delivery
of EV cargo [52,53]. Focusing on RCC, Grange et al. demonstrated that CSC-derived EVs isolated
from clear-cell RCC are the main mediators for the inhibition of DC differentiation and maturation
from monocytes [54]. In particular, DCs that differentiated in the presence of renal CSC EVs expressed
a low level of costimulatory molecules CD80 and CD86; other activation markers, such as CD83
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and CD40; and the antigen-presenting molecule HLA-DR. Moreover, DCs that are differentiated in
the presence of renal CSC EVs were unable to induce T lymphocyte proliferation and they released
anti-inflammatory cytokines, such as IL-10 [54]. One of the main players of this inhibitory effect was
the non-classical HLA class I molecule, HLA-G. HLA-G was previously described to abrogate NK,
T cell and DC functions [55]. In addition, HLA-G has been found to be overexpressed in 50% of
clear-cell RCCs [56]. Moreover, EVs isolated from human kidney adenocarcinoma were able to induce
T lymphocyte apoptosis through the activity of FAS ligand expressed on their surface [57] (Figure 1).
2.5. Effect of RCC-EVs on the Premetastatic Niche
The metastatic niche is defined as a number of molecular and cellular changes in the metastatic
designated organs that favor tumor cell colonization and sustain tumor establishment in a distant
site [58]. All the components of secretomes, including soluble factors, EVs, exosomes and microvesicles,
support this process, creating a complex network of information exchanges [59,60].
A crucial step to initiate the process for tumor cell dissemination from a primary to foreign site
is the stimulation of vascular permeability [39]. Zeng et al. demonstrated that miR-25-3p, released
by colorectal cancer exosomes, is transferred to tumor endothelial cells, which results in increased
vascular permeability and consequently increased metastasis formation. miR-25-3p targets Krüppel-like
factor 2 (KLF2) and Krüppel-like factor 4 (KLF4), a family of zinc finger-containing transcription
factors [39]. KLF2 inhibits angiogenesis by reducing the activity of VEGFR2 while KLF4 is involved
in the maintenance of endothelial barrier integrity and acts on tight junction proteins, such as ZO-1,
occludin and claudin 5 [61].
In RCC and prostate cancer, the ability to promote the premetastatic niche formation was mainly
retained by CSCs EVs rather than by those derived from the tumor bulk [30,62]. In fact, EVs released
by renal CSCs and not by differentiated tumor cells enhance the formation of lung metastases by
the upregulation of MMP2, MMP9 and VEGF receptors by lung endothelial cells [30]. Comparing
the miRNA profile of the EV populations released by CSCs and differentiated tumor cells, it has
been shown that renal CSC EVs were enriched with miRNAs that may influence biological pathways
related to cell growth, cell matrix adhesion and survival [30]. In particular, these EVs shuttled several
miRNAs, such as miR-19a, miR-19b, miR-650 and miR-151, which were previously associated with
tumor invasion and metastases (Table 1) [63–65]. Recently, a similar approach was applied by Sanchez
et al. for the comparative analysis of miRNA content in prostate cancer and prostate CSC EVs
using next generation sequencing [62]. miR-100-5p and miR-21-5p have been described as the most
abundant miRNAs while the differentially expressed miRNAs were predicted to be involved in prostate
carcinogenesis, fibroblast proliferation, differentiation and angiogenesis [62]. The overexpression of
miRNA-183 was found in EVs that were shed by renal and prostate CSCs [30,62] (Figure 1).
2.6. RCC-EV oncomiRNAs
miRNAs are 19–22 bp non-coding RNAs involved in the regulation of biological processes by the
post-transcriptional downregulation of one or more target genes. MiRNAs bind to a complementary
sequence that is present in target mRNA, which leads to its degradation [66]. To date, the number
of miRNAs annotated in human genome is continuously increasing and it can be speculated that
the majority of protein-coding genes are targeted by at least one miRNA [67]. In the last few years,
numerous reports have shown the importance of miRNAs in the regulation of cancer related biological
processes [68]. During tumor progression, miRNAs can act as oncogene or tumor suppressors
depending on their mRNA targets and on the cellular context. All the miRNAs that inhibit tumor
suppressor proteins involved in relevant processes, such as cell cycle, apoptosis, DNA damage and
chemoresistance, are generally defined as “oncomiRNAs” [69,70]. Several oncomiRNAs have been
identified in renal CSC EVs and are discussed above for their pro-tumorigenic role (Table 1) [30].
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Table 1. OncomiRNAs carried by renal CSC EVs. The table lists some of the oncomiRNAs carried
by renal CSC EVs and highlights their targets in renal cell carcinoma and the renal samples used to
identify specific miRNAs.
miRNAs Targets in RCC Renal Samples Reference
miR-183 Dickkopf-related protein-3 (DKK-3)Protein phosphatase 2A
Renal CSC EVs
Renal tumor cells
Renal cancer tissues
Serum of RCC patients
Grange et al. [30]
Qiu et al. [71]
Zhang et al. [72]
miR-486 TGF-β-activated kinase 1
Renal CSC EVs
Renal tumor cells
Renal cancer tissues
Grange et al. [30]
He et al. [73]
Goto et al. [74]
miR-19a
PTEN
SMAD4
RhoB
PIK3CA
Renal CSC EVs
Renal cancer tissues
Grange et al. [30]
Ma et al. [75]
Xiao et al. [76]
Niu et al. [77]
miR-92 VHL Renal CSC EVsRenal cancer tissues
Valera et al. [78]
Grange et al. [30]
miR-19b RhoBPTEN/PI3K/AKT Signalling Pathway Renal CSC EVs
Grange et al. [30]
Niu et al. [77]
Liu et al. [79]
miR-650 Not determined Renal CSC EVs Grange et al. [30]
miR-151 Not determined Renal CSC EVs Grange et al. [30]
miR-301 Not determined Renal CSC EVs Grange et al. [30]
2.6.1. miR-183
miR-183 belongs to the miR-183-96-182 cluster, which has an upregulated expression in many
solid tumors, including RCC [72]. The expression of miR-183 was increased in tumor specimens
compared to their healthy counterparts and its role in promoting invasion and metastasis was
demonstrated in RCC lines [80]. Indeed, high levels of miR-183 were also detected in the sera from
RCC patients and was inversely correlated with the cytotoxicity of NKs compared to tumor cells
in vitro, thus suggesting a possible application of miR-183 detection in patients’ sera as a prognostic
marker for immunotherapy [80]. Finally, Li et al. analysed the sera from 284 RCC patients that
underwent nephrectomy and demonstrated a positive correlation between miR-183 level and poor
prognosis [81]. miR-183 promotes tumor cell proliferation and invasion by targeting Dickkopf-related
protein-3 (DKK-3), a negative regulator of the Wnt signaling pathway [80], and the tumor suppressor
protein phosphatase 2A, one of the main regulators of AKT signaling [71].
2.6.2. miR-486
Goto et al. analysed formalin-fixed paraffin-embedded specimens from RCC patients and
identified miR-486 as a possible biomarker for poor prognosis [74]. Indeed, He et al. recently
demonstrated the role of miR-486 in promoting proliferation and inhibiting apoptosis of RCC cell lines
in vitro [73]. miR-486 has been proposed to be a negative regulator of multiple targets involved in
PTEN/PI3K/Akt, FOXO and TGF-b/Smad2 signaling [82].
2.6.3. miR-92, miR-19a and miR-19b
miR-92, miR-19a and miR-19b are components of the miR-17-92 cluster, which is also called
Oncomir-1. The cluster consists of six miRNAs, namely miR-17, miR-18a, miR-19a, miR-20a, miR-19b
and miR-92a, and was found to be upregulated in many solid tumors, including RCC [79,83].
The components of the miR-17-92 cluster target the genes involved in proliferation and survival,
thus inhibiting apoptosis and increasing cell proliferation, invasion and escape from immune system [84].
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In RCC, miR-92 targets the tumor suppressor gene VHL, which allows the stabilization of HIFs, a crucial
point during RCC progression as discussed above [78]. miR-19a, targeting PTEN [75] and RhoB [77],
influences both proliferation and invasiveness of RCC cells. Finally, miR-19a has been described to be
overexpressed in RCC tissues and especially has been shown to be upregulated in metastatic RCC
compared to primary tumor tissues [75]. For these reasons, miR-19a has been proposed as a possible
prognostic biomarker for RCC [76].
2.6.4. miR-650
miR-650 has been described as an oncomiRNA involved in the metastatic progression of different
solid tumors, such as gastric cancer [64], prostate cancer [85], colorectal cancer [86], hepatocellular
carcinoma [87] and oral cancer [88]. Although the presence of high levels of miR-650 has been reported
in renal CSC EVs, the role of this oncomiRNA in RCC progression is not yet fully understood.
2.6.5. miR-301
An in vitro study on breast cancer cells described miR-301 as one of the central oncomiRNAs in
breast cancer [89], with miR-301 being involved in many steps of tumorigenesis through multi-target
activity and its expression was associated with the presence of distant metastasis [90]. miR-301 was
also detected in both small cell carcinoma specimens [91] and in EVs isolated from non small cell lung
cancer patients [92]. Although both authors proposed miR-301 as a possible biomarker for lung cancer,
the study of Silva et al. failed to demonstrate that this miRNA could discriminate between healthy and
cancer patients [92].
2.7. Long Non-Coding RNAs in RCC-EVs
It is increasingly evident that in many types of EVs, other forms of non-coding RNAs, such as
long non-coding RNAs (lncRNA), are more represented than miRNAs [93]. LncRNAs are a class of
transcripts with a length of 200 bp or longer than regulate gene expression at various levels. Indeed,
lncRNAs can control cell transcription and protein translation by interacting with proteins, mRNAs
or miRNAs [94]. LncRNAs have been reported to regulate different steps of tumorigenesis, such as
cell proliferation, apoptosis and invasion, and may also have diagnostic value [95]. Interestingly,
a recent study identified an lncRNA, namely lncARSR (for lncRNA Activated in RCC with Sunitinib
Resistance), in RCC tissue and the tumor released EVs [96]. LncARSR promoted Sunitinib resistance
through the regulation of miR-34/miR-449, thus facilitating AXL and c-MET expression in RCC cells.
Moreover, the intracellular transfer of lncARSR by RCC-EVs disseminated resistance to Sunitinib and
targeting this could restore the drug response. The role of the lnc-RNAs is of great interest in tumor EV
biology although further studies are needed to identify EV- and circulating-lncRNAs and to better
dissect their role in RCC and RCC-derived EVs.
3. Circulating miRNAs in RCC
In the last decade, it has been discovered that miRNAs are present at high levels in the bloodstream
of cancer patients [35]. Circulating miRNAs are ideal candidates for diagnostic purposes since they can
be isolated in a non-invasive manner from biologic fluids. miRNA stability depends on the presence
of circulating RNAse and it is increased when miRNAs are bound to lipoproteins or encapsulated in
EVs. Many studies were recently focused on the identification of miRNAs as possible diagnostic and
prognostic biomarkers for RCC [97] (Table 2).
In 2011, Wulfken et al. published the first study that aimed to identify the miRNA signature in
the sera of RCC patients [97]. The analysis of blood samples from 190 patients (93 healthy and 97
cancer patients) identified 36 miRNAs that were differentially expressed between healthy people’s
and patients’ sera. Among them, only miR-1233 was validated as a possible biomarker for diagnostic
purposes [97].
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Other miRNAs were subsequently identified in patients’ sera and were proposed as candidates
for RCC diagnosis as potential biomarkers in RCC [98–104]. In particular, a large-scale analysis on
both healthy subjects and cancer patients before and after nephrectomy highlighted the combination of
miR-210 and miR-378 as potential biomarkers for early tumor detection [105].
As shown in Table 2, each study identified a different subset of circulating miRNAs, highlighting
the absence of correspondence among the studies. Indeed, a genome-wide screening on circulating
miRNAs in both early and late stage renal carcinoma patients detected a subset of 27 miRNAs that
were differentially expressed between early and late stage patients [106]. However, authors do not
support the use of circulating miRNA as diagnostic or prognostic biomarkers since the expression of
the identified miRNAs were not significantly correlated with tumor progression.
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Table 2. Circulating miRNAs in RCC patients. The table lists some of the circulating miRNAs isolated in serum of RCC patients and specifies the screening technique,
screening groups and results.
miRNA ScreeningTechnique miRNA Source Screening Groups Validation Groups Study Results References
miR-378
Real time PCR Serum 25 healthy controls25 RCC
123 healthy controls
117 RCC
miR-378 levels were higher in RCC screening
group versus healthy controls, but results were
not validated.
Hauser et al. [104]
Real time PCR Serum 15 healthy controls12 RCC
35 healthy controls
90 RCC
Validation of the increase of miR-378 in patients’
sera, in combination with the downregulation of
the antitumor miR-451.
Redova et al. [98]
Real time PCR Serum 100 healthy controls195 RCC Not performed
Diagnostic and prognostic value of miR-378
increase, in combination with miR-210 increase. Fedorko et al. [105]
miR-221 Real time PCR Plasma 34 healthy controls44 RCC Not performed
miR-221 levels positively correlate with
progression towards a metastatic disease and
inversely correlate with survival rate.
Teixeira et al. [101]
miR-210
Real time PCR Tissue samplesand serum
32 RCC tissues samples (tumor and adjacent
healthy tissue); sera from 42 healthy controls,
68 RCC before and
10 RCC patients after nephrectomy
Not performed
Increased levels of miR-210 both in tissue samples
(compared to adjacent healthy tissue) and in
RCC sera.
Zhao et al. [99]
Real time PCR Tissue samplesand serum
23 healthy controls
34 RCC Not performed
Increased levels of miR-210 in RCC sera compared
to controls. No correlation with tumor stage. Iwamoto et al. [100]
Real time PCR Serum 100 healthy controls195 RCC Not performed
Increased levels of miR-210 in RCC sera
compared to controls. Prognostic value in
combination with miR-378.
Fedorko et al. [105]
Real time PCR Serum EV
80 healthy controls,
82 RCC before nephrectomy
10 RCC after nephrectomy.
Not performed Higher content in miR-210 and miR-1233 in EVisolated from RCC patients’ sera. Zhang et al. [107]
Meta analysis Serum Not performed
7 studies:
415 healthy controls
570 RCC
Validation of the potential diagnostic value
of miR-210. Chen et al. [108]
miR-193a TaqMan LowDensity Array Serum
25 healthy controls
25 RCC
107 healthy controls
107 RCC Increased in RCC sera. Wang et al. [102]
miR-362 TaqMan LowDensity Array Serum
25 healthy controls
25 RCC
107 healthy controls
107 RCC Increased in RCC sera. Wang et al. [102]
miR-572 TaqMan LowDensity Array Serum
25 healthy controls
25 RCC
107 healthy controls
107 RCC Increased in RCC sera. Wang et al. [102]
Int. J. Mol. Sci. 2019, 20, 1832 10 of 16
Table 2. Cont.
miRNA ScreeningTechnique miRNA Source Screening Groups Validation Groups Study Results References
miR-1233
TaqMan Low
Density Array
Tissue samples
and serum 6 healthy controls and 6 RCC
93 healthy controls
and 84 RCC
miR-1233 was identified and validated as
increased in RCC. Wulfken et al. [97]
Real Time PCR SerumEPCAM+ EV
80 healthy controls,
82 RCC before nephrectomy
10 RCC after nephrectomy.
Not performed Higher content in miR-210 and miR-1233 in EVisolated from RCC patients’ sera. Zhang et al. [107]
miR-99b Sequencing Tissue samples 40 RCC (tumor and adjacent healthy tissue) 65 RCC miR-99b levels positively correlated with tumorprogression after TKI therapy
Lukamowicz et
al. [109]
miR-21 Real Time PCR Serum 30 healthy controls30 RCC before and after nephrectomy Not performed Increased levels in RCC sera. Tusong et al. [110]
miR-106a Real Time PCR Serum 30 healthy controls30 RCC before and after nephrectomy Not performed Increased levels in RCC sera. Tusong et al. [110]
miR-122-5p small RNAsequencing Serum
8 benign renal tumors
18 RCC
28 healthy controls
47 benign renal
tumors
68 RCC
Correlation of miR-122 levels with metastatic
progression and survival
Heinemann et
al. [103]
miR-206 small RNAsequencing Serum
8 benign renal tumors
18 RCC
28 healthy controls
47 benign renal
tumors
68 RCC
Correlation of miR-122 levels with metastatic
progression and survival
Heinemann et
al. [103]
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4. Conclusions
The crosstalk between all cell types within the tumor, including non-malignant cells, is pivotal
in tumor maintenance. RCC-EVs and even more renal CSC-EVs sustain tumor growth by acting on
several aspects of renal tumor progression, such as tumor proliferation, angiogenesis, immunoescape
and metastasis formation. The complexity of the EV cargo (mRNAs, proteins and especially miRNAs)
is the basis for the multi-target activity described above, involved in the reprogramming of target cells.
Therefore, the development of strategies to interfere with EV mediated intercellular communication is
now considered to be a challenging therapeutic option. In addition, tumor EVs have been proposed as
new biomarkers for tumor diagnosis due to their high amount in biological fluids and increased stability
compared to non-EV encapsulated molecules. However, in RCC, the identification of a prognostic
miRNA still requires further standardization and validation.
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